Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 12/20 | 0.69 |
| ▸ | IKBKB | O14920 | 5/20 | 0.68 |
| ▸ | CHUK | O15111 | 5/20 | 0.68 |
| ▸ | AKT1 | P31749 | 5/20 | 0.68 |
| ▸ | AKT2 | P31751 | 5/20 | 0.68 |
| ▸ | AKT3 | Q9Y243 | 5/20 | 0.68 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457364 | 1.00 | PADI4 (0.69) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL16111508 | 0.90 | PADI4 (0.74) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL16111509 | 0.90 | PADI4 (0.74) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6489833 | 0.90 | PADI4 (0.71) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6489837 | 0.90 | PADI4 (0.71) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6494010 | 0.88 | PADI4 (0.69) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6494012 | 0.88 | PADI4 (0.69) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL16111025 | 0.88 | PADI4 (0.71) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL16111027 | 0.88 | PADI4 (0.71) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6479411 | 0.87 | PADI4 (0.67) | PADI4IKBKBCHUKAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968360-B1 | QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2019-11-14 | — | — | US | disclosed |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.